Angelica Welch

Articles

Novel Agents, Genetic Testing Propel Personalized Care in Ovarian Cancer

August 29th 2018

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Falchook Sheds Light on Rare Oncogenic Drivers in NSCLC

August 28th 2018

Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.

Deferred Treatment Beneficial in Some Patients With MCL

August 24th 2018

Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.

Ansell Addresses Immune Evasion in Hodgkin Lymphoma

August 24th 2018

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.

Transparency Vital in the Dawning Age of Biosimilars in Oncology

August 24th 2018

Gary H. Lyman, MD, FASCO, interprets the available information on biosimilars as it relates to the clinical oncology community.

Esteva Discusses Promise of Trastuzumab Biosimilar Candidate

August 22nd 2018

Francisco J. Esteva, MD, PhD, discusses the journey of CT-P6 and its promise as a potential biosimilar for trastuzumab in the United States.

Expert Navigates Through Expanding Therapeutic Options in NETs

August 21st 2018

Scott Paulson, MD, discusses recent updates in the treatment of patients with neuroendocrine tumors.

SL-401 Emerging as First Targeted Therapy for Rare Blood Cancer

August 16th 2018

Naveen Pemmaraju, MD, discusses SL-401 and the future of treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

Drilon Discusses Promise of LOXO-292 in RET-Altered Solid Tumors

August 16th 2018

Alexander E. Drilon, MD, discusses the data with LOXO-292 thus far and the promise for this agent in patients with RET alterations.

Importance of NGS and Targetable Mutations Stressed in AML

August 15th 2018

Suman Kambhampati, MD, discusses the impact of next-generation sequencing on treatment selection, updates in the inhibition of BCL-2, IDH1/2, and FLT3-ITD, and new agents on the horizon for the treatment of patients with acute myeloid leukemia.

CNS Metastases Remain Unmet Need in HER2+ Breast Cancer

August 14th 2018

Kevin Kalinsky, MD, discusses the current treatment landscape of metastatic HER2-positive breast cancer, the potential for immunotherapy, and what is on the horizon for patients in this population who develop brain metastases.

Kahl Looks Toward the Future in MCL

August 13th 2018

Brad Kahl, MD, discusses the exciting new advancements on the horizon for the treatment of patients with mantle cell lymphoma.

Expert Shares Insight on Analyses From S-TRAC Trial in RCC

August 13th 2018

Daniel J. George, MD, discusses an analysis of RCC patients in the S-TRAC trial with the highest risk of recurrence, and potential prognostic factors of DFS that emerged from the study.

Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer

August 11th 2018

Abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to Lowell L. Hart, MD.

The State of HER2+ Breast Cancer in the Curative Setting

August 10th 2018

Rashmi K. Murthy, MD, discusses selecting therapy for patients with HER2-positive breast cancer in the curative setting.

Sznol Reflects on Immunotherapy Advances in mRCC

August 9th 2018

Mario Sznol, MD, discusses the latest developments with immunotherapy in metastatic renal cell carcinoma.

Expert Emphasizes Inclusivity in Prostate Cancer Trials

August 8th 2018

Daniel J. George, MD, discusses the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

ctDNA Emerges as Promising Biomarker for Lymphoma

August 7th 2018

David M. Kurtz, MD, PhD, discusses the clinical use of circulating tumor DNA in lymphoma.

Borghaei Discusses Nivolumab/Ipilimumab CheckMate-227 NSCLC Findings

August 6th 2018

Hossein Borghaei, DO, MS, discusses the results of the subgroup analysis of the ongoing CheckMate-227 trial in metastatic non–small cell lung cancer.

Yardley Recaps Breast Cancer Data From ASCO 2018

August 2nd 2018

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.